Based in Irvine, California, Micro Therapeutics is a leading provider of interventional neurovascular devices. The company’s core products are built on two meaningfully differentiated treatment technologies, the Onyx liquid embolic system and NXT embolic coils, designed to treat a broad range of cerebral vascular malformations including aneurysms, the leading cause of hemorrhagic stroke. In addition to its Onyx and NXT product offerings, the company currently manufactures and sells a range of guide wires, balloon catheters and infusion micro-catheters engineered to access the tiny arteries within the brain. Since leading a $55 million investment in Micro Therapeutics in 2001, Warburg Pincus has led three additional PIPE financings totaling more than $50 million to fund the company’s clinical programs and product development strategy, including the acquisition of a German manufacturer of neurovascular products. ev3 acquired Micro Therapeutics in January 2006.

Back to Previous Page